A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1

Structure

Volumn 17, Issue 11, 2009, Pages 1476-1484

  Huang, Ren Huai ^a   Fremont, Daved H ^a   Diener, John L ^b   Schaub, Robert G ^b   Sadler, J Evan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Archemix Corporation   (United States)

Author keywords

DNA

Indexed keywords

ALANINE; ANTITHROMBOCYTIC AGENT; APTAMER; ARC 1172; ARGININE; BOTROCETIN; CATION; GLYCINE; GLYCOPROTEIN IB ALPHA; LYSINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BASE PAIRING; BINDING KINETICS; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FIBRINOLYTIC THERAPY; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

APTAMERS, NUCLEOTIDE; BINDING SITES; CRYSTALLOGRAPHY; FIBRINOLYTIC AGENTS; HUMANS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; PROTEIN BINDING; VON WILLEBRAND FACTOR;

EID: 70350705718     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2009.09.011     Document Type: Article

References (47)

1. Andrews R.K., Gorman J.J., Booth W.J., Corino G.L., Castaldi P.A., and Berndt M.C. Cross-linking of a monomeric 39/34-kDa dispase fragment of von Willebrand factor (Leu-480/Val-481-Gly-718) to the N-terminal region of the α-chain of membrane glycoprotein Ib on intact platelets with bis(sulfosuccinimidyl) suberate. Biochemistry 28 (1989) 8326-8336
2. Baker C.M., and Grant G.H. Role of aromatic amino acids in protein-nucleic acid recognition. Biopolymers 85 (2007) 456-470
3. Baker N.A., Sept D., Joseph S., Holst M.J., and McCammon J.A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98 (2001) 10037-10041
4. Bock L.C., Griffin L.C., Latham J.A., Vermaas E.H., and Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355 (1992) 564-566
5. Carugo O., and Pongor S. A normalized root-mean-square distance for comparing protein three-dimensional structures. Protein Sci. 10 (2001) 1470-1473
6. Celikel R., Varughese K.I., Madhusudan, Yoshioka A., Ware J., and Ruggeri Z.M. Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat. Struct. Biol. 5 (1998) 189-194
7. syn base-pair: a unique d(GXC) loop closure motif. J. Mol. Biol. 329 (2003) 351-361
8. Chou S.H., Chin K.H., and Wang A.H. Unusual DNA duplex and hairpin motifs. Nucleic Acids Res. 31 (2003) 2461-2474
9. Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr 50 (1994) 760-763
10. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall III W.B., Snoeyink J., Richardson J.S., and Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (2007) W375-W383
11. De Meyer S.F., Vanhoorelbeke K., Broos K., Salles I.I., and Deckmyn H. Antiplatelet drugs. Br. J. Haematol. 142 (2008) 515-528
12. Diener J., Daniel Lagasse H.A., Duerschmied D., Merhi Y., Tanguay J.F., Hutabarat R., Gilbert J., Wagner D.D., and Schaub R. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by anti-von Willebrand Factor A1-domain aptamer ARC1779. J. Thromb. Haemost. 7 (2009) 1155-1162
13. Diener J.L., and Lagassé D.H.A. Aptamers to von Wlllebrand factor and their use as thrombotic disease therapeutics (2006), Archemix Corp., Cambridge, MA
14. Dumas J.J., Kumar R., McDonagh T., Sullivan F., Stahl M.L., Somers W.S., and Mosyak L. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibα complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J. Biol. Chem. 279 (2004) 23327-23334
15. Ellington A.D., and Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990) 818-822
16. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
17. Emsley J., Cruz M., Handin R., and Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J. Biol. Chem. 273 (1998) 10396-10401
18. Fukuda K., Doggett T.A., Bankston L.A., Cruz M.A., Diacovo T.G., and Liddington R.C. Structural basis of von Willebrand factor activation by the snake toxin botrocetin. Structure 10 (2002) 943-950
19. Fukuda K., Doggett T., Laurenzi I.J., Liddington R.C., and Diacovo T.G. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat. Struct. Mol. Biol. 12 (2005) 152-159
20. Gilbert J.C., DeFeo-Fraulini T., Hutabarat R.M., Horvath C.J., Merlino P.G., Marsh H.N., Healy J.M., Boufakhreddine S., Holohan T.V., and Schaub R.G. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116 (2007) 2678-2686
21. Huizinga E.G., Tsuji S., Romijn R.A., Schiphorst M.E., de Groot P.G., Sixma J.J., and Gros P. Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science 297 (2002) 1176-1179
22. Keefe A.D., and Schaub R.G. Aptamers as candidate therapeutics for cardiovascular indications. Curr. Opin. Pharmacol. 8 (2008) 147-152
23. Knobl P., Jilma B., Gilbert J.C., Hutabarat R.M., Wagner P.G., and Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion (2009) Published online June 15, 2009
24. Lagasse H.A.D., Merlino P.G., Marsh H.N., Makim A., Lewis S.D., and Diener J.L. Discovery and characterization of a potent neutralizing anti-VWF A1 domain specific aptamer. J. Thromb. Haemost. (2007) 665
25. Laskowski R.A., Macarthur M.W., Moss D.S., and Thornton J.M. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
26. Long S.B., Long M.B., White R.R., and Sullenger B.A. Crystal structure of an RNA aptamer bound to thrombin. RNA 14 (2008) 2504-2512
27. Luscombe N.M., Laskowski R.A., and Thornton J.M. NUCPLOT: a program to generate schematic diagrams of protein-nucleic acid interactions. Nucleic Acids Res. 25 (1997) 4940-4945
28. Maita N., Nishio K., Nishimoto E., Matsui T., Shikamoto Y., Morita T., Sadler J.E., and Mizuno H. Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibα binding mechanism induced by snake venom proteins. J. Biol. Chem. 278 (2003) 37777-37781
29. Mao L., Wang Y., Liu Y., and Hu X. Multiple intermolecular interaction modes of positively charged residues with adenine in ATP-binding proteins. J. Am. Chem. Soc. 125 (2003) 14216-14217
30. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
31. Ng E.W., Shima D.T., Calias P., Cunningham Jr. E.T., Guyer D.R., and Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5 (2006) 123-132
32. Nimjee S.M., Rusconi C.P., and Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56 (2005) 555-583
33. Oney S., Nimjee S.M., Layzer J., Que-Gewirth N., Ginsburg D., Becker R.C., Arepally G., and Sullenger B.A. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17 (2007) 265-274
34. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
35. Padmanabhan K., and Tulinsky A. An ambiguous structure of a DNA 15-mer thrombin complex. Acta Crystallogr. D Biol. Crystallogr. 52 (1996) 272-282
36. Rooman M., Lievin J., Buisine E., and Wintjens R. Cation-π/H-bond stair motifs at protein-DNA interfaces. J. Mol. Biol. 319 (2002) 67-76
37. Sadler J.E. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67 (1998) 395-424
38. Sathyapriya R., Vijayabaskar M.S., and Vishveshwara S. Insights into protein-DNA interactions through structure network analysis. PLoS Comput. Biol. 4 (2008) e1000170
39. Sathyapriya R., and Vishveshwara S. Interaction of DNA with clusters of amino acids in proteins. Nucleic Acids Res. 32 (2004) 4109-4118
40. Spiel A.O., Mayr F.B., Ladani N., Wagner P.G., Schaub R.G., Gilbert J.C., and Jilma B. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 20 (2009) 334-340
41. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
42. Ulrichts H., Udvardy M., Lenting P.J., Pareyn I., Vandeputte N., Vanhoorelbeke K., and Deckmyn H. Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J. Biol. Chem. 281 (2006) 4699-4707
43. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30 (1997) 1022-1025
44. Winn M.D., Isupov M.N., and Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57 (2001) 122-133
45. Wintjens R., Lievin J., Rooman M., and Buisine E. Contribution of cation-π interactions to the stability of protein-DNA complexes. J. Mol. Biol. 302 (2000) 395-410
46. Zhang P., Pan W., Rux A.H., Sachais B.S., and Zheng X.L. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 110 (2007) 1887-1894
47. Zwart P.H., Afonine P.V., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., McKee E., Moriarty N.W., Read R.J., Sacchettini J.C., et al. Automated structure solution with the PHENIX suite. Methods Mol. Biol. 426 (2008) 419-435